Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study to Evaluate Humanized CD19-Specific CAR T Cells Following Lymphodepleting Chemotherapy in Adult Patients With Relapsed/Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia

NCT06447987 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT06447987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06447987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study to Evaluate Humanized CD19-Specific CAR T Cells Following Lymphodepleting Chemotherapy in Adult Patients With Relapsed/Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Suspended
Start date
November 6, 2024
Completion date
December 5, 2026
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent acute lymphoblastic leukemia, refractory acute lymphoblastic leukemia